# James G. Christensen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/james-g-christensen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 46,794 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 86 |
| i10-index | 173 |
| OpenAlex ID | https://openalex.org/A5074923974 |
| ORCID iD | https://orcid.org/0000-0003-1835-0335 |
| Works | 998 |

## Researcher papers

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling](https://scholariq.org/papers/i-met-i-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating/)
- [Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors](https://scholariq.org/papers/genotypic-and-histological-evolution-of-lung-cancers-acquiring-resistance-to/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation](https://scholariq.org/papers/adagrasib-in-non-small-cell-lung-cancer-harboring-a-i-kras-sup-g12c-sup-i/)
- [<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression](https://scholariq.org/papers/i-met-i-exon-14-mutations-in-non-small-cell-lung-cancer-are-associated-with/)
- [Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer](https://scholariq.org/papers/functional-expression-and-mutations-of-c-met-and-its-therapeutic-inhibition-with/)
- [Institutional implementation of clinical tumor profiling on an unselected cancer population](https://scholariq.org/papers/institutional-implementation-of-clinical-tumor-profiling-on-an-unselected-cancer/)
- [<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib](https://scholariq.org/papers/i-met-i-amplification-identifies-a-small-and-aggressive-subgroup-of/)
- [The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers](https://scholariq.org/papers/the-neuroblastoma-associated-f1174l-alk-mutation-causes-resistance-to-an-alk/)
- [MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer](https://scholariq.org/papers/mrtx1719-is-an-mta-cooperative-prmt5-inhibitor-that-exhibits-synthetic-lethality/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Liver physiology and pathology](https://scholariq.org/topics/liver-physiology-and-pathology/)
- [Cancer-related gene regulation](https://scholariq.org/topics/cancer-related-gene-regulation/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.